PubMed · 16425673
Ispronicline (Targacept).
Abstract
Targacept (formerly a subsidiary of RJ Reynolds) is developing ispronicline, the lead in a series of nicotinic acetylcholine (nACh) ligands, as a potential oral treatment for cognitive impairment, including a variety of non-Alzheimer's dementias. In July 2005, Targacept was preparing for a phase II study in patients with mild-to-moderate Alzheimer's disease.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Hugo Geerts. 2006. Ispronicline (Targacept).. https://pubmed.ncbi.nlm.nih.gov/16425673/
Cite the original work for its findings. Save a collection to share your selection of sources.